Discover how High-throughput Spectral Shift (HT-SpS) technology accelerates binder and molecular glue discovery for some of the most challenging targets, including proteins with allosteric sites and complex protein–protein interactions.

Novel Alternative Methods (NAMs) are emerging as an important strategy for improving the success rate in drug discovery.

Obesity is a complex, multifactorial disease that presents major hurdles for drug discovery and development.

The need for efficient and innovative drug discovery chemistry strategies to support novel modalities like Degraders, ADCs (Antibody-Drug Conjugates), and other complex therapeutics has never been greater.

Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Discover how in vitro and computational tools reduce the reliance on animal testing and support smarter, earlier decision-making in drug discovery.

ADC (Antibody-Drug Conjugate) drug discovery is a specialised approach in pharmaceutical research and development that focuses on creating targeted therapies. ADCs combine the targeting ability of monoclonal antibodies with the cell-killing power of cytotoxic drugs. The goal is to deliver a potent drug directly to the target cells while minimising damage to healthy surrounding tissue.